source
- AstraZeneca's breast cancer drug camizestrant fails pivotal first-line trialAstraZeneca announced that its investigational breast cancer drug camizestrant did not meet primary endpoints in a pivotal Phase 3 trial evaluating it as a first-line treatment for advanced disease…
- AstraZeneca's Etcamah fails late-stage trial for early-stage breast cancer useAstraZeneca announced that its newly approved breast cancer therapy, Etcamah, did not meet its primary goals in a pivotal study aimed at expanding the drug's label. The trial evaluated Etcamah in…